CL2015001702A1 - Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c. - Google Patents

Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.

Info

Publication number
CL2015001702A1
CL2015001702A1 CL2015001702A CL2015001702A CL2015001702A1 CL 2015001702 A1 CL2015001702 A1 CL 2015001702A1 CL 2015001702 A CL2015001702 A CL 2015001702A CL 2015001702 A CL2015001702 A CL 2015001702A CL 2015001702 A1 CL2015001702 A1 CL 2015001702A1
Authority
CL
Chile
Prior art keywords
tricyclic
hepatitis
treatment
pharmaceutical composition
antiviral compounds
Prior art date
Application number
CL2015001702A
Other languages
English (en)
Inventor
John O Link
Jeromy J Cottell
Elizabeth M Bacon
Teresa Alejandra Trejo-Martin
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50974893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001702(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CL2015001702A1 publication Critical patent/CL2015001702A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
CL2015001702A 2012-12-21 2015-06-17 Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c. CL2015001702A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745452P 2012-12-21 2012-12-21
US13/830,346 US9233974B2 (en) 2012-12-21 2013-03-14 Antiviral compounds

Publications (1)

Publication Number Publication Date
CL2015001702A1 true CL2015001702A1 (es) 2015-08-07

Family

ID=50974893

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001702A CL2015001702A1 (es) 2012-12-21 2015-06-17 Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.

Country Status (28)

Country Link
US (5) US9233974B2 (es)
EP (3) EP2935279B1 (es)
JP (1) JP6333849B2 (es)
KR (2) KR102164390B1 (es)
CN (2) CN107011350A (es)
AP (1) AP2015008511A0 (es)
AR (1) AR094262A1 (es)
AU (1) AU2013361195B2 (es)
BR (1) BR112015014333A8 (es)
CA (1) CA2893963C (es)
CL (1) CL2015001702A1 (es)
CR (1) CR20150370A (es)
EA (2) EA201790781A3 (es)
ES (1) ES2626392T3 (es)
HK (3) HK1214594A1 (es)
IL (1) IL239496A0 (es)
MA (1) MA38261A1 (es)
MD (1) MD20150062A2 (es)
MX (1) MX2015007888A (es)
PE (1) PE20151423A1 (es)
PH (1) PH12015501354A1 (es)
PL (1) PL2935279T3 (es)
PT (1) PT2935279T (es)
SG (1) SG11201504746PA (es)
SI (1) SI2935279T1 (es)
TW (2) TWI613202B (es)
UY (1) UY35241A (es)
WO (1) WO2014100500A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11485753B2 (en) 2012-12-21 2022-11-01 Janssen Pharmaceutica Nv Substituted nucleosides, nucleotides and analogs thereof

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011328980B2 (en) 2010-11-17 2015-07-30 Gilead Pharmasset Llc Antiviral compounds
PL2635588T3 (pl) 2011-11-16 2015-10-30 Gilead Pharmasset Llc Skondensowane imidazoliloimidazole jako związki antywirusowe
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
US9398640B2 (en) 2012-12-21 2016-07-19 Halliburton Energy Services, Inc. Digital multi-use thermo-cup
US9096596B2 (en) 2013-03-14 2015-08-04 Janssen Pharmaceutica Nv P2X7 modulators
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
TW201522307A (zh) 2013-03-14 2015-06-16 百靈佳殷格翰國際股份有限公司 經取代２－氮雜－雙環［２．２．１］庚烷－３－羧酸（苄基－氰基－甲基）－醯胺組織蛋白酶ｃ抑制劑
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
CN105530933B (zh) 2013-07-17 2018-12-11 百时美施贵宝公司 用于治疗hcv的包含联苯衍生物的组合产品
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
CR20160574A (es) 2014-06-17 2017-02-23 Pfizer Compuestos de dihidroisoquinolinona sustituida
JP6592510B2 (ja) 2014-09-12 2019-10-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節因子
SI3191487T1 (sl) 2014-09-12 2019-12-31 Boehringer Ingelheim International Gmbh Spirociklični inhibitorji katepsina C
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
CN110372559A (zh) * 2014-12-29 2019-10-25 重庆博腾制药科技股份有限公司 一种(4S)-N-Boc-4--甲氧基甲基-L-脯氨酸的合成方法
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN105732765B (zh) * 2016-02-01 2019-07-26 杭州科巢生物科技有限公司 丙肝药物维帕他韦的新合成方法
CN106916134B (zh) * 2016-04-14 2020-04-17 苏州楚凯药业有限公司 一种10,11-二氢-5H-苯并[d]萘并[2,3-b]吡喃酮衍生物的制备方法
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
MX2018014377A (es) 2016-05-27 2019-03-14 Gilead Sciences Inc Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3).
CN106831737B (zh) * 2017-02-27 2020-03-17 上海众强药业有限公司 维帕他韦及其衍生物的制备
EP3684374A4 (en) * 2017-09-21 2021-06-16 Riboscience LLC 4'-FLUORO-2'-METHYL SUBSTITUTE NUCLEOSIDE DERIVATIVES USED AS HCV RNA REPLICATION INHIBITORS
SG11202004403QA (en) 2017-12-07 2020-06-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US20200102311A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol Lipase Modulators
EP3856178A1 (en) 2018-09-28 2021-08-04 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
EP4038070A1 (en) 2019-09-30 2022-08-10 Janssen Pharmaceutica NV Radiolabelled mgl pet ligands
KR20220157999A (ko) 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제
WO2022246109A1 (en) * 2021-05-21 2022-11-24 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
BRPI0513426A (pt) 2004-07-16 2007-11-27 Gilead Sciences Inc processo de preparação de amino ácidos úteis na preparação de moduladores de receptores de peptìdeos
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2398474A4 (en) * 2009-02-23 2012-12-05 Presidio Pharmaceuticals Inc HCV NS5A SHEMMER
AU2011328980B2 (en) 2010-11-17 2015-07-30 Gilead Pharmasset Llc Antiviral compounds
US8552047B2 (en) * 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US20130309196A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11485753B2 (en) 2012-12-21 2022-11-01 Janssen Pharmaceutica Nv Substituted nucleosides, nucleotides and analogs thereof

Also Published As

Publication number Publication date
CR20150370A (es) 2015-08-14
CN107011350A (zh) 2017-08-04
HK1216177A1 (zh) 2016-10-21
TWI613202B (zh) 2018-02-01
US20160083395A1 (en) 2016-03-24
JP6333849B2 (ja) 2018-05-30
KR20200118903A (ko) 2020-10-16
KR102164390B1 (ko) 2020-10-12
ES2626392T3 (es) 2017-07-24
TW201835087A (zh) 2018-10-01
CA2893963C (en) 2021-09-07
HK1214594A1 (zh) 2016-07-29
AU2013361195B2 (en) 2018-05-17
CN104918943A (zh) 2015-09-16
AU2013361195A1 (en) 2015-06-11
EA201590868A1 (ru) 2015-11-30
US9233974B2 (en) 2016-01-12
MD20150062A2 (ro) 2015-12-31
EP2935279B1 (en) 2017-03-15
PE20151423A1 (es) 2015-10-17
US20180244684A1 (en) 2018-08-30
US20140178336A1 (en) 2014-06-26
HK1245263A1 (zh) 2018-08-24
MX2015007888A (es) 2015-09-29
BR112015014333A2 (pt) 2017-07-11
US20170369502A1 (en) 2017-12-28
SG11201504746PA (en) 2015-07-30
JP2016503800A (ja) 2016-02-08
BR112015014333A8 (pt) 2019-10-15
PH12015501354A1 (en) 2015-09-07
WO2014100500A1 (en) 2014-06-26
IL239496A0 (en) 2015-08-31
EP2935279A1 (en) 2015-10-28
EA201790781A2 (ru) 2017-08-31
SI2935279T1 (sl) 2017-06-30
AR094262A1 (es) 2015-07-22
AP2015008511A0 (en) 2015-06-30
MA38261A1 (fr) 2017-06-30
EP3239152A1 (en) 2017-11-01
EP3404030A1 (en) 2018-11-21
PL2935279T3 (pl) 2017-08-31
TW201441229A (zh) 2014-11-01
US20160362416A1 (en) 2016-12-15
EA201790781A3 (ru) 2017-11-30
CA2893963A1 (en) 2014-06-26
UY35241A (es) 2014-07-31
EA027828B1 (ru) 2017-09-29
CN104918943B (zh) 2017-04-05
KR20150100728A (ko) 2015-09-02
PT2935279T (pt) 2017-06-02

Similar Documents

Publication Publication Date Title
CL2015001702A1 (es) Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2016001509A1 (es) Formas cristalinas de los análogos de sofosbuvir antivirales
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
CL2015001342A1 (es) Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2015000784A1 (es) Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades.
CL2014001858A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
CR20150380A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
CL2015001731A1 (es) Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
CL2015001699A1 (es) Compuestos derivados de nucleosidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y su uso para preparar un medicamento util en el tratamiento de la hepatitis c.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2015003444A1 (es) Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
CL2013002939A1 (es) Compuestos derivados de nucleosidos 2´-sustituidos , inhibidores ns5a; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
CL2014002726A1 (es) Compuestos derivados de pirrolopirimidina y purina; composicion farmaceutica; utiles en el tratamiento del cancer (div. sol. 566-14).
CL2014002557A1 (es) Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras.
CO6950473A2 (es) Novedosos derivados de purina y su uso en el tratamiento de enfermedades
CL2013001891A1 (es) Compuestos heterociclicos fusionados; composicion farmaceutica y uso en el tratamiento de la degeneracion macular asociada con la edad.
CL2013002125A1 (es) Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia.
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2014001047A1 (es) Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas.
CL2013001754A1 (es) Compuestos derivados de enonas triciclicas y tetraciclicas de pirazolilo y pirimidinilo; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades inflamatorias.